The recent revolution in –omics technology and the advent of targeted and immune therapies have increased the interest in molecular biomarkers capable of predicting the diagnostic, the clinical outcome of cancer patients or the response to specific therapies. The development of stratified medicine implies the segmentation of common cancers in small groups of tumors with specific abnormalities.

Lire la suite

Theme 1 "Clinical Trial Methodology" A new generation of clinical trial designs requiring repeated biomarker measurements and surrogate clinical endpoints is needed to evaluate treatment effects in trials with limited sample sizes.

Theme 2 "Meta-analysis of treatments and biomarkers” Large-scale collaborative individual patient data (IPD) meta-analyses are useful tools to provide high level of evidence on the efficacy and toxicity of anti-cancer therapies in molecularly defined strata .With the increasing number of therapies available for a specific indication in oncology, methods for network meta-analysis are being developed to compare their effectiveness.

Theme 3 "Economic evaluation of treatments and biomarkers" Because of the high costs associated with the tandem diagnostic and therapeutic medicine, economic analyses will be needed to evaluate the strategy associating the biomarkers with the molecularly targeted treatments, which represents a new field of research.

Theme 4 "Development and validation of biomarkers ".Once a potential biomarker has been identified for the prediction of diagnosis or clinical outcome of patients, an evidence-based evaluation implies careful replication in other cohorts. Advances in molecular genetics and in the knowledge of pathology of cancer are re-shaping the traditional methods in clinical epidemiology.

The Oncostat team is currently labelled Ligue Contre le Cancer (League Against Cancer).

The statistical software packages developed in the team are available to the scientific community on the website https://oncostat.github.io/



Hôpital Gustave Roussy, Bat. B2M

114 rue Edouard Vaillant
94805 Villejuif

Principaux Financeurs
Union Européenne


Dernières publications

Penalized Poisson model for network meta-analysis of individual patient time-to-event data. OLLIER Edouard, Blanchard Pierre, LE TEUFF Gwénaël, MICHIELS Stefan. . 2021; :
Long-term longitudinal patterns of patient-reported fatigue after breast cancer: A group-based trajectory analysis. A. Di Meglio, J. Havas, M. El-Mouhebb, P. Lapidari, D. Presti, D. Soldato, B. Pistilli, A. Dumas, G. Menvielle, C. Charles, S. Everhard, A.L. Martin, P.H. Cottu, F. Lerebours, C. Coutant, S. Dauchy, S. Delaloge, N. Lin, P. Ganz, A.H. Partridge, F. André, and S. Michiels. . 2021; :
Biomarker Discovery and Validation: Statistical Considerations. Fang-Shu Ou, PhD,a, Stefan Michiels, PhD,b Yu Shyr, PhD,c Alex A. Adjei, MD, PhD,d Ann L. Oberg, PhD. Journal of Thoracic Oncology. 2021; 16: p.537-545. doi:org/10.1016/j.jtho.2021.01.1616
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life. M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget. . 2020; : . doi:10.1002/cncr.32554
[Does sentinel lymph node identification has indication in digestive cancers?]. Faron, M.; Laas, E.. Bull Cancer. 2019; : . doi:10.1016/j.bulcan.2019.06.013


Identification de sous-groupes à l'aide de biomarqueurs de grande dimension dans les essais randomisés. Dirigée par Stefan Michiels & Federico Rotolo. Belhechmi Shaima . []: Paris Sud; .
Coût et efficience des nouvelles stratégies thérapeutiques guidées par la biologie moléculaire en cancérologie. BAYLE Arnaud. []: ; .
Méta-analyses sur données individuelles d’essais randomisés dans les cancers de l’estomac en situation avancée ou métastatique : Analyse de l’efficacité et de la toxicité de l’Irinotecan. . Chamseddine Ali. []: ; .
Apport clinique des méta-analyses dans les cancers ORL localement avancés. Benjamin Lacas. []: ; .